Rawlins County THCa Rick Simpson Oil: OilWell Cannabis Houston’s 16,590mg 7-Cannabinoid RSO Sublingual with 1,500mg Patient-Controlled THCa for Up to 1,405mg Delta-9 THC—Bentley’s 10-Year Miracle Legacy, ABC13-Featured, Baylor College of Medicine-Connected, Texas DSHS Licensed, Farm Bill-Compliant, Nationwide Shipping

Rick Simpson Oil in Rawlins County: The Complete Guide for Kansas Patients and Families

Rawlins County sits at the heart of western Kansas, where the wheat fields stretch to the horizon and the community runs deep. We know that out here, when someone’s hurting—whether it’s a farmer’s chronic back pain from decades in the field, a veteran’s PTSD from service in faraway places, or a neighbor facing the terrifying uncertainty of a cancer diagnosis—people turn to their community first. They ask friends, they talk at the grain elevator, they seek solutions that make sense for rural life. That’s exactly why we created this guide for Rawlins County residents. We’re not here to sell you hope or make promises we can’t keep. We’re here to give you the complete, honest story about Rick Simpson Oil—what it is, what it isn’t, and how our modern, multi-cannabinoid RSO formulas might fit into your healthcare journey.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or medical professional—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began with personal suffering and a deep distrust of the medical system that failed him. We share his story here in Rawlins County not because we endorse every claim he made, but because his experience resonates with what so many Kansans face: when conventional medicine doesn’t have answers, people start looking elsewhere.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine couldn’t resolve. The medications prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused. That refusal—familiar to many Rawlins County residents who’ve broached alternative treatments with conservative medical providers—became the catalyst for everything that followed.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, where THC was reported to slow or shrink tumors in mice. That study, originally intended to demonstrate harm, became a foundational reference point in Simpson’s advocacy, even though its findings were never replicated in controlled human cancer trials. We mention this because we know Rawlins County residents are practical people—they understand the difference between promising lab results and proven human treatments. The 1974 study is historically interesting, but it’s not clinical proof.

The 2003 Basal Cell Carcinoma Story

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

For Rawlins County residents dealing with skin cancer—common in agricultural communities with high sun exposure—this story resonates. But we must be clear: while Simpson’s experience is compelling, it’s not medical proof. If you’re facing skin cancer in Atwood or McDonald, please consult with a dermatologist. Simpson’s method was anecdotal, not clinical.

The Crusade: Spreading the Oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil from his property in Maccan, Nova Scotia. He gave it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others.

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials, and framed his work as a grassroots challenge to pharmaceutical interests. It was distributed freely online and became foundational in cannabis communities. For many Rawlins County residents who first learned about cannabis oil through online forums or word-of-mouth, Run From The Cure was likely their introduction.

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005 and 2009. He was charged with cultivation, possession, and trafficking. Facing continued legal pressure, Simpson eventually left Canada for Europe, living in Croatia and the Netherlands, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story and maintained phoenixtears.ca as his primary platform. Throughout his public career, Simpson maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge.

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding RSO’s cultural significance. Institutional distrust exists everywhere, and in Rawlins County—where pharmaceutical access can be limited and healthcare options are fewer—some residents may share Simpson’s skepticism. Our goal is to present the evidence honestly and let you decide.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core recommendation was a structured oral protocol designed to deliver 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment protocol, though he recommended it for numerous other conditions. Here’s the detailed breakdown:

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration Schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake: approximately 30 to 45 milligrams.
• Weeks 2 through 5: Double the dose approximately every four days to build THC tolerance gradually. By the end of this period—roughly four to five weeks—the target is to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.
• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed.

Administration Methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method, though he acknowledged inhalation for immediate symptom relief.

Tolerance and Psychoactive Effects

• Simpson maintained that patients would develop significant tolerance to THC’s psychoactive effects within approximately three to four weeks of consistent dosing.
• He considered euphoric, sedating, or disorienting effects a minor and temporary side effect and urged patients not to let the high discourage them from continuing.
• He recommended taking initial doses at night to sleep through the most intense psychoactive effects during early titration.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and inform family members about what to expect.

Important Context for Evaluating This Protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, or formal research. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content varied widely depending on starting plant material and extraction technique.
• Very high THC exposure. At peak dosing, patients consumed roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the GENERAL KNOWLEDGE section [15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

For Rawlins County residents considering this protocol, we must be direct: this is not a medically validated treatment. The nearest oncology centers are hours away in Denver or Wichita—delaying proven treatment to follow an unproven protocol could have devastating consequences. If you’re facing cancer, please work with an oncologist. RSO may be a complementary option, but it should never replace conventional care.

What is Traditional Rick Simpson Oil—the Product?

Traditional RSO refers to the specific type of concentrated cannabis oil Simpson made and advocated for. It was defined not by lab specifications but by his method and materials.

Source Material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa strains for cancer treatment. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

For Rawlins County residents who understand agriculture, this variability is a red flag. In farming, consistency in seed genetics, soil conditions, and harvest timing determines crop quality. Simpson’s approach had none of that consistency—every batch was different. That variability meant every batch of traditional RSO had unpredictable potency and effects.

Extraction Solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid. He later endorsed 99 percent isopropyl alcohol as an alternative. He explicitly warned against using other solvents like butane or acetone.

Critical safety issue: Neither naphtha nor isopropyl alcohol is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic or carcinogenic compounds. Incomplete solvent purging—which is very difficult to verify without lab testing—leaves potentially harmful residues in the finished oil. For Rawlins County residents who value clean, safe products, this is the #1 problem with traditional RSO production.

Extraction Process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. Material was covered with solvent and agitated for several minutes.
3. Solvent was poured off through a filter into a separate vessel.
4. Process was repeated with fresh solvent on the same plant material.
5. Combined solvent washes were placed in a rice cooker.
6. Solvent was evaporated at relatively low heat. Simpson recommended a rice cooker because it maintains a temperature range that evaporates solvent without excessive cannabinoid degradation—but it was still hot enough to decarboxylate THCa into THC and destroy most volatile terpenes.
7. As solvent evaporated, thick, dark oil remained.
8. Final oil was transferred into oral syringes for storage and dosing.

This DIY process may appeal to Rawlins County’s self-reliant culture, but the safety risks are significant. The solvent fumes are flammable—a real danger in home kitchens. Without lab testing, there’s no way to verify solvent removal. Modern extraction uses food-grade ethanol or supercritical CO₂ specifically to address these problems.

Appearance and Physical Characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell. The consistency was sticky and difficult to handle at room temperature.

This is a far cry from OilWell’s modern formulation, which uses organic MCT oil as a carrier, creating a product that’s easier to dose, more pleasant to use, and free from solvent residues.

Cannabinoid Profile

• Primarily decarboxylated delta-9 THC. The heat converted essentially all THCa into delta-9 THC. Traditional RSO was an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. The profile was entirely determined by genetics and growing conditions.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight—though this was never lab-verified.

Terpene Content

Minimal to none. The combination of solvent extraction and high-heat evaporation meant traditional RSO was effectively stripped of its terpene content. This is a significant distinction from modern formulations that deliberately preserve terpenes.

For Rawlins County residents who appreciate the aromatic complexity of cannabis, traditional RSO missed this dimension entirely. The terpene profile matters not just for smell and taste but for the potential entourage effect.

Standardization and Testing

None. Every batch was different because it depended on starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

In modern Kansas agriculture, we test everything—soil, seeds, livestock feed. The idea of consuming a product with zero quality control would be unthinkable. Yet that’s exactly what traditional RSO was.

Residual Solvent Risk

This is one of the most significant safety concerns. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging—which is difficult to verify without lab testing—leaves potentially harmful residues.

For Rawlins County residents who maintain their own equipment and understand contamination risks, this should be a major concern. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to eliminate this risk. OilWell’s solvent-free production approach completely eliminates this hazard.

Simpson’s Claims vs. the Evidence Record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career.

It’s important to evaluate these claims against the actual evidence base, using the same standards we apply throughout this document.

What Simpson Was Not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the Preclinical Literature Shows

The preclinical cannabinoid-cancer literature does exist and is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines.
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids.
• These findings have generated legitimate scientific interest and ongoing research.

However—and this is critical—these findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.

Institutional Positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment.
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What He Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature.

For Rawlins County residents facing cancer, we cannot be more direct: Do not replace proven cancer treatment with RSO. The nearest comprehensive cancer centers are hours away—at the University of Kansas Cancer Center in Kansas City, or MD Anderson in Houston. Making that journey is hard, and we know rural healthcare access is a real challenge. But delaying or foregoing treatment based on unproven claims can be life-threatening. RSO may be a complementary option, but it should never replace conventional care.

The Legacy of Rick Simpson and the Evolution of Modern RSO

The term RSO is now used broadly—and often loosely—across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use. The term has become generic.

Simpson himself has been critical of commercial products that use the RSO name while departing significantly from his original method and philosophy. He has publicly stated that many products sold as RSO do not meet his standards and that the commercialization of cannabis oil contradicts his original intent. Simpson’s model was explicitly anti-commercial—he gave the oil away for free and urged others to make their own rather than buy from companies.

This philosophical tension is worth acknowledging. Simpson believed in a do-it-yourself, free-access model in which anyone could grow cannabis, extract the oil, and treat themselves or their loved ones without corporate or governmental intermediaries. The modern cannabis industry has done something very different: it has commercialized, standardized, and regulated what Simpson distributed for free. Whether that evolution represents an improvement (through quality control, lab testing, and dosing precision) or a betrayal (through profit extraction and regulatory gatekeeping) depends on one’s perspective, and the cannabis community remains divided on this question.

What is not in dispute is that modern RSO has evolved substantially from its origins, and those changes are directly relevant to the formulas in this document.

Traditional RSO vs. Modern Formulated RSO

The following table summarizes the key differences between traditional RSO as Simpson defined it and the modern formulated approach used in OilWell’s products.

Dimension	Traditional RSO	OilWell Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes at 5% with defined seven-terpene profile
Standardization	None—every batch different	Lab-tested with specific mg/mL targets (553mg/mL)
Lab testing	Not available or performed	Full panel testing, COAs available
Residual solvents	Significant risk with naphtha	Controlled and tested, solvent-free production
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
Product formats	Single thick oil only	Sublingual oil and vape cartridge with format-specific formulas
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient at 1,500mg
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted
Legal access (Rawlins County)	Illegal—Schedule I substance	Farm Bill compliant, ships to Kansas legally

Why OilWell’s Formulas Diverge from Traditional RSO

OilWell’s formulations are not traditional RSO. They are informed by the RSO tradition but depart from it in several deliberate, evidence-motivated ways.

• Multi-cannabinoid approach. Traditional RSO relied on whatever single strain the maker grew or sourced. OilWell’s formulas intentionally include seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests potential benefit from cannabinoid diversity, even though robust clinical proof of whole-formula synergy remains limited [20][29].

• Terpene preservation and addition. Traditional RSO had essentially no terpene content due to solvent and heat destruction. OilWell includes live terpenes at 5% with a specific seven-terpene profile—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—because terpene bioactivity is plausible and supported at the preclinical level, even if human clinical confirmation for cannabis-specific terpene effects is still developing [20][21][23][24][25][26][27][28][29].

• THCa as a separate ingredient. Traditional RSO fully decarboxylated everything, converting all THCa into delta-9 THC. OilWell’s sublingual formula includes THCa at 1,500mg as a distinct ingredient, preserving the acidic precursor because the THCa literature suggests potentially relevant non-psychoactive bioactivity that is lost when THCa converts to THC [12].

• Reduced delta-9 THC dominance. Traditional RSO was overwhelmingly delta-9 THC—often 60 to 90% of total cannabinoid content. OilWell’s formula uses delta-9 THC at only 90mg while incorporating delta-8 THC at 6,000mg and distributing the remaining cannabinoid content across CBD (4,500mg), CBG (3,000mg), CBN (750mg), and CBC (750mg). This reflects the broader cannabinoid research landscape rather than a single-compound dominance model.

• Product format innovation. Simpson envisioned only one format: an oral oil administered from a syringe. OilWell offers both a 30mL sublingual oil and a 1-gram vape cartridge, each with its own format-specific formulation acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent Safety and Extraction Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, and other toxic compounds. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil.

Modern cannabis extraction overwhelmingly uses food-grade ethanol or supercritical carbon dioxide (CO₂). These methods allow for much more complete solvent removal, and the finished products can be tested for residual solvents using validated analytical methods such as headspace gas chromatography. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over the traditional RSO production model.

For Rawlins County residents who maintain their own equipment and understand contamination risks, this evolution matters. You wouldn’t use contaminated fuel in your combine—you shouldn’t use contaminated solvents in medicine you ingest.

The Decarboxylation Question

Traditional RSO was fully decarboxylated. The heat involved in evaporating solvent from the rice cooker—typically sustained at or near the boiling point of the solvent—was sufficient to convert essentially all THCa in the extract into delta-9 THC. This meant the acidic cannabinoids that exist abundantly in raw cannabis were lost as distinct compounds.

OilWell’s sublingual formula deliberately preserves THCa at 1,500mg as a separate ingredient. This is an intentional formulation choice informed by the THCa evidence profile, which notes that THCa itself does not produce the psychoactive effects associated with THC but that its interpretation depends on route, temperature, processing, and storage—because THCa can convert to THC under heating or over time [12].

For Rawlins County residents who need to work, drive tractors, operate machinery, or stay clear-headed during the day, this distinction is transformative. The same product can be used raw (non-psychoactive) for daytime relief or activated (psychoactive) for nighttime use. You control the decision, not the product.

Terpene Loss in Traditional RSO

Terpenes are volatile aromatic compounds with relatively low boiling points. Most cannabis terpenes begin to volatilize at temperatures between 21 and 157 degrees Celsius, with many of the most abundant terpenes—including myrcene, limonene, and pinene—having boiling points below 180 degrees Celsius. The traditional RSO production process destroyed terpenes in two ways: first, by dissolving them into the solvent wash along with cannabinoids; and second, by evaporating them off during the high-heat solvent-removal phase.

This meant that traditional RSO was essentially a cannabinoid-only product, despite being derived from a terpene-rich plant. Whatever aromatic, flavoring, or potentially bioactive terpene compounds the source cannabis contained were lost in production.

OilWell’s formulas specify live terpenes at 5% with a defined seven-terpene profile: limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene. Each of these terpenes has its own evidence profile discussed in the GENERAL KNOWLEDGE section. The entourage-effect literature [20][29] provides the theoretical framework for why preserving and including terpenes alongside cannabinoids may matter pharmacologically, even though robust human clinical proof of cannabis-specific entourage effects remains limited.

For Rawlins County residents familiar with essential oils, aromatherapy, or the distinctive smell of pine trees and citrus orchards, terpenes are intuitive. They’re the compounds that give plants their characteristic aromas, and they may contribute to the therapeutic experience.

Evidence Standards Then and Now

Rick Simpson operated in a pre-legalization, pre-lab-testing era. When he began making and distributing oil in the early 2000s, cannabis was illegal in Canada and throughout most of the world. There was no regulatory framework for cannabis products, no standardized testing infrastructure, no legal pathway for clinical research on cannabis oil protocols, and no peer-reviewed journals dedicated to cannabis therapeutics. The cannabis underground was the only access point, and personal experience was the primary evidence currency.

Simpson’s methods reflected the constraints of that era. His evidence was anecdotal. His production was unstandardized. His claims were untested in any formal sense. This is not necessarily a moral failing—it is a description of the environment in which he operated.

This document takes a fundamentally different approach. The GENERAL KNOWLEDGE section applies a formal evidence hierarchy: human clinical evidence first, then systematic reviews and meta-analyses, then institutional summaries, then preclinical and mechanistic literature [1]-[29]. Every compound-level claim is tied to specific peer-reviewed sources with evidence strength clearly labeled. The intent is to honor the historical origin of RSO while committing to the standards of modern cannabinoid science.

Simpson’s Protocol vs. Modern Dosing Considerations

Simpson’s 60-gram/90-day protocol was designed around a crude, single-strain, THC-dominant extract with no standardized potency. A direct comparison between Simpson’s dosing recommendations and dosing with a modern, standardized, multi-cannabinoid formulation is not straightforward—the products are fundamentally different.

Several key differences illustrate why:

• Cannabinoid concentration. OilWell’s sublingual formula delivers 553mg of total active cannabinoids per mL across seven defined compounds. Traditional RSO potency was unknown and variable.
• Cannabinoid ratios. Simpson’s oil was approximately 60 to 90% delta-9 THC. OilWell’s formula distributes 16,590mg of total cannabinoids across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), THCa (1,500mg), delta-9 THC (90mg), CBN (750mg), and CBC (750mg)—a completely different pharmacologic profile.
• Delta-9 THC exposure. Simpson’s protocol at peak dosing delivered approximately 600 to 900mg of delta-9 THC per day. OilWell’s sublingual formula contains only 90mg of delta-9 THC in the entire 30mL bottle (3mg per mL), making per-dose delta-9 THC exposure dramatically lower.

Future dosing guidance for OilWell products should be developed independently of Simpson’s protocol, informed by the per-compound evidence in the GENERAL KNOWLEDGE section and by responsible titration principles that account for the safety profile of each individual cannabinoid.

References for This Section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.

RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.

RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.

RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.

RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.

RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ) — Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

ABOUT OILWELL CANNABIS AND THE OILWELL RSO FORMULA

The Origin of OilWell Cannabis

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of retail and healthcare. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity, making it a harsh environment for anyone growing up there.

Colin’s childhood in McAllen was marked by exposure to both the opportunities and the challenges of life along the border. Early on, he learned to hustle, taking on risky work in transporting items across the border for various groups. Those early experiences exposed him to complexities and dangers. A lot of his best friends have been killed or are in prison because of the associated dangers. He has faced every form of violence imaginable, both in the streets and across the border. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths available to him, like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define OilWell’s approach.

For Rawlins County residents, this origin story matters. We know what it means to come from a place where opportunities are limited and challenges are real. We understand that character is forged through adversity. Colin didn’t start from privilege—he started from a place more dangerous and difficult than most Rawlins County residents can imagine. That authenticity carries through everything we do.

Bentley’s Story: A Dog Who Changed Everything

The company’s origin story begins with a dog named Bentley. Bentley was more than just a pet—he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss and seen too much suffering in his life. Bentley was a fighter, just like him, and Colin was not ready to let him go. In a desperate search for alternatives, he stumbled upon the healing properties of CBD—through a question that changed everything.

A kind-hearted rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored the therapeutic and medicinal applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline—and it was hope. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. It was a miracle. From paralyzed and facing euthanasia to fetching his ball. This was not placebo effect—dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led him to understand CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led him to CBC’s role in neurogenesis. Glaucoma led him to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led him to develop multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

For Rawlins County pet owners, this story resonates deeply. We know that out here, a dog isn’t just a pet—it’s a working partner, a family member, a piece of your heart. When conventional veterinary medicine says there’s no hope, you’ll try anything. Bentley’s story proves that cannabinoid medicine can deliver real results.

Colin’s Personal Journey: PTSD, Benzo Addiction, and Finding Relief

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat that is notoriously difficult and dangerous—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became an OilWell product was created during midnight experiments while fighting through benzo withdrawal. To ensure quick relief, OilWell also offers the Peace Gummies formula in a vape form, which Colin personally uses to manage his insomnia and severe PTSD on an ongoing basis.

This is not theoretical knowledge. Colin lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

For Rawlins County veterans and others dealing with PTSD, this matters. We have veterans in Atwood, McDonald, and Herndon who’ve struggled with the VA system, been prescribed benzos, and found themselves trapped. Colin’s story shows there’s another path—one that doesn’t require choosing between suffering and addiction.

Community Impact and Recognition

ABC13 KTRK Houston—Houston’s number-one news source—featured Colin and OilWell Cannabis in seven comprehensive news segments spanning 2019 to 2023, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering. Colin was repeatedly selected as the primary industry expert for cannabis policy and product coverage in America’s fourth-largest city.

Seven features. Five different reporters. Four years. That kind of sustained media attention doesn’t happen by accident. It happens when journalists trust your expertise, your integrity, and your willingness to speak honestly—even when it’s uncomfortable.

For Rawlins County residents, this media record matters because it establishes credibility that transcends geography. When a major-market ABC affiliate repeatedly chooses the same expert, it’s because that expert has proven reliable. You can verify every ABC13 segment online. You can see Colin’s interviews, hear his quotes, watch him explain complex cannabis issues with clarity and honesty. That’s the kind of third-party validation no marketing budget can buy.

Our Philosophy for Rawlins County

OilWell’s RSO is not traditional Rick Simpson Oil. It is a formulated, multi-cannabinoid product informed by the RSO tradition but departing from it in ways that are deliberate, evidence-motivated, and designed to solve the problems that limited Rick Simpson’s original vision.

Four core principles define our approach, each aligning with and evolving Simpson’s original ethos:

1. Accessibility over gatekeeping. No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide—including to Rawlins County, Kansas. Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

2. Patient-controlled potency. THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

3. Open-source formulas. We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford the product can source ingredients and make their own version. Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

4. Evidence-informed, not evidence-overstating. The GENERAL KNOWLEDGE section in this document represents our commitment to honest education about what the science actually says. Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access and use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance: Legal Access for Rawlins County

The 2018 Farm Bill (Agricultural Improvement Act) legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight at the federal level. This legal framework is the foundation of OilWell’s RSO product design.

Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30mL bottle—3 milligrams per milliliter—well under the 0.3% threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and in Kansas.

THCa—the legal key for Kansas residents: THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

The practical significance for Rawlins County residents is substantial. You can legally purchase, possess, and transport our product in Kansas. The nearest law enforcement is the Rawlins County Sheriff’s Office in Atwood and the Kansas Highway Patrol—both enforce state and federal law. Our product complies with both. You can have it shipped directly to your home in Atwood, McDonald, Herndon, or anywhere in Rawlins County without legal risk.

Important legal notice: While our product is legal under federal law and Kansas state law, THCa converts to delta-9 THC when heated. You are responsible for understanding and complying with local laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis (COAs), and receipts. International customers (including those in Canada or Mexico) must verify legality in their jurisdiction and accept all customs and legal risk.

For Rawlins County residents, this legal clarity is crucial. You don’t have to drive to Colorado or risk illegal possession. You can order a Farm Bill compliant product that delivers the therapeutic potential you’re seeking within the bounds of Kansas law.

The Decarboxylation Choice: Patient-Controlled Potency

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving the patient with no choice about psychoactivity—the oil was always psychoactive.

OilWell’s sublingual formula contains 1,500 milligrams of THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 milligrams stays as THCa—completely non-psychoactive. The THCa evidence profile describes potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment. For Rawlins County farmers who need to operate equipment at dawn, this means relief without impairment.

Option 2—Fully activated, home decarboxylation. Heating the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container converts 1,500 milligrams of THCa into approximately 1,315 milligrams of delta-9 THC. Combined with the existing 90 milligrams of delta-9 THC, this yields approximately 1,405 milligrams of total delta-9 THC. Combined with 6,000 milligrams of delta-8 THC, the activated product achieves psychoactive potency comparable to traditional high-THC RSO—100% legally, because decarboxylation occurs at your discretion after purchase. You may also transfer a controlled portion from the original bottle into a second oven-safe container, decarboxylating only what you intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. The RSO Vape Cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

Conversion chemistry: THCa has a molecular weight of 358.47 g/mol. The conversion ratio is approximately 1 milligram THCa = 0.877 milligrams delta-9 THC after decarboxylation, reflecting the loss of a CO₂ molecule during the reaction.

This design puts the potency decision entirely in your hands—aligning with Rick Simpson’s principle that patients should control their own medicine, but implementing that principle through actual product chemistry rather than a one-size-fits-all approach.

Solvent-Free Production

OilWell’s RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

This approach eliminates the residual solvent risk that is one of the most significant safety concerns with traditional RSO production.

The product uses organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile—a significant improvement over the tar-like consistency and solvent-residual odor of traditional RSO.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

For Rawlins County residents who maintain equipment and understand the importance of maintenance and testing, this quality control should resonate. You test your well water, you test your soil, you should test what you put in your body.

Our Broader Product Portfolio

Beyond RSO, OilWell Cannabis produces a range of cannabinoid products, each developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal.

Asshole Peach—our most popular product. Asshole Peach is a carefully formulated experience designed to provide a euphoric, long-lasting sensation. It is particularly favored by veterans for its ability to relieve pain and PTSD symptoms without being overly aggressive. For Rawlins County veterans who’ve struggled to find relief through the VA system, this product has been transformative.

Peace Gummies—developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Peace Gummies helped him quit Xanax cold turkey. The formula is also available in a vape form for quick relief—Colin personally uses the vape to manage his insomnia and severe PTSD on an ongoing basis.

Custom creations—we offer custom-made products tailored to the specific needs of individual customers. Whether it involves specific cannabinoid ratios, particular delivery formats, or formulations for unique health circumstances, we design targeted products on request. This includes formulations for vegans, diabetics, and those with specific dietary or health needs.

Two Product Formats

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30mL bottle (1 fl oz)
• 16,590mg total cannabinoids (553mg per mL)
• Seven cannabinoids: CBD 4,500mg, CBG 3,000mg, delta-8 THC 6,000mg, THCa 1,500mg, delta-9 THC 90mg, CBN 750mg, CBC 750mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1mL increments
• Onset: 15 to 45 minutes (sublingual absorption)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Approximately 40 to 60 doses per bottle

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery method)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

For Rawlins County residents, having both formats means flexibility. The sublingual oil is ideal for sustained daily relief—take it before heading out to the fields, and it lasts through the day. The vape is for breakthrough moments—when pain spikes suddenly or panic hits hard, relief comes in minutes.

When to Use Each Format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring required
Precise dosing control	Sublingual	Graduated dropper in 0.1mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Competitive Comparison

OilWell RSO vs. Traditional Illegal RSO
We covered this in the traditional vs. modern comparison table above. The key differences: 7 cannabinoids vs. THC-only, solvent-free vs. naphtha, lab-tested vs. untested, legal vs. illegal.

OilWell RSO vs. Hemp CBD Products
Most hemp-derived “RSO” products contain only CBD and trace amounts of other cannabinoids. Our formula delivers 16,590mg total cannabinoids across 7 compounds, including meaningful amounts of delta-8 THC and THCa. For Rawlins County residents who’ve tried CBD-only products without success, the difference is the entourage effect—you’re getting a full-spectrum, multi-cannabinoid approach.

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research cited in the GENERAL KNOWLEDGE section and by our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-related nausea and appetite support

• Pre-chemo: 0.5 to 1.0mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support: 1.0 to 2.0mL sublingual before bed (delivers 25 to 50mg CBN)

For Rawlins County cancer patients traveling to Wichita or Denver for treatment, this protocol can help manage treatment side effects. The pre-chemo dose can be taken before you leave Atwood for your appointment. The vape can be used in the car for immediate relief if nausea hits during the drive home.

Chronic pain (fibromyalgia, arthritis, neuropathy)

• Daytime: 0.3 to 0.5mL raw sublingual—anti-inflammatory without psychoactive impairment
• Nighttime: 0.5 to 1.0mL decarboxylated sublingual—combines pain relief with sleep support
• Breakthrough pain: Vape as needed for rapid onset

For Rawlins County farmers and ranchers whose bodies bear the cumulative toll of physical labor, this approach addresses pain without compromising your ability to work. The raw daytime option lets you function. The activated nighttime option helps you rest and recover.

Sleep support

• Before bed: 1.0 to 2.0mL sublingual
• At 2.0mL, this delivers 50mg CBN—the dosage level investigated in the 2024 sleep literature
• At 1.0mL, this delivers 25mg CBN—above the 20mg threshold associated with reduced sleep disturbance

For Rawlins County residents struggling with insomnia—a common issue in agricultural communities where early mornings are mandatory—this natural alternative to prescription sleep aids can be life-changing.

Anxiety and stress

• Daytime functional relief: 0.3mL raw sublingual—CBD and CBG address anxiety without impairment
• Nighttime: 1.0mL sublingual—full cannabinoid profile including CBN for sleep architecture

For Rawlins County residents dealing with the stress of farm economy volatility, family pressures, or isolation in rural living, this provides relief without the fog of benzodiazepines or SSRIs.

General titration principle: Start low, go slow. Begin with 0.25 to 0.5mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, and concurrent medications.

Delivery to Rawlins County

We ship to Rawlins County via USPS Priority Mail (2-3 business days) from our Houston facility. Every package includes:

• Full documentation and Certificates of Analysis
• Discreet packaging with no cannabis branding visible
• Temperature-stable packaging for Kansas weather
• Tracking information

For Rawlins County residents, this means reliable access without leaving home. No driving to Colorado. No legal risk. The product arrives at your door with complete documentation.

International shipping note: While we ship internationally, Rawlins County residents should know that Kansas law is what matters for you. Our product is legal in Kansas under the Farm Bill. If you travel internationally, you’re responsible for verifying destination country laws.

How Our Formulas Connect to the Evidence

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile in the GENERAL KNOWLEDGE section. Every terpene—limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene—is covered with preclinical and review-level evidence.

Our formulas are anchored to per-compound evidence summaries that explain what is well-supported by human clinical data, what is emerging from review and preclinical literature, and what is overstated relative to the current evidence base. We do not exempt ourselves from the same evidence standards applied to the broader cannabinoid field.

As Colin Valencia said in that first ABC13 feature in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

That philosophy—honest education, no hype, patient empowerment—guides everything we do for Rawlins County residents.

MEDIA RECOGNITION AND COMMUNITY IMPACT

Colin Valencia: Houston’s Go-To Cannabis Authority

Between September 2019 and April 2023, ABC13 Houston (KTRK)—the ABC affiliate serving America’s fourth-largest city—featured Colin Valencia and OilWell Cannabis in seven distinct news segments spanning business, law, medicine, community health, and politics. Five different ABC13 reporters sought Colin out across those years: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff writers.

No other Houston cannabis operator appears with that frequency or across that breadth of subject matter during the same period. For Rawlins County residents evaluating credibility, this matters. When a major-market ABC affiliate consistently chooses the same expert across four years, it’s because that expert has proven reliable.

Media Record Highlights Relevant to Rawlins County

September 2019: “Texas CBD businesses booming”
Colin’s foundational quote: “I’m not trying to sell people snake oil… I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

This quote—spoken years before our formulas were published—is the seed of everything OilWell became.

May 2021: “What is Delta 8 THC”
Steve Campion’s iconic exchange:

• Campion: “Why would someone want to smoke that?”
• Colin: “I don’t give a sh** if it’s wrong to say you’ll get high off it. Maybe you want to get high.”

That radical honesty on mainstream television—with the expletive preserved—demonstrates the unfiltered truthfulness that defines our approach.

August 2021: COVID Vaccine Giveaway
We gave away 1,000 caviar pre-rolls (approximately $35,000 in product) to encourage COVID-19 vaccination in Houston. We coordinated with the city government. No political strings. For Rawlins County residents, this demonstrates community commitment that goes beyond profit.

October 2021: Delta-8 Ban
When Texas classified Delta-8 as Schedule I overnight, Colin proactively removed all Delta-8 products before enforcement began and tried to warn other operators who were unknowingly shipping Schedule I narcotics. This ethical leadership—absorbing revenue loss to act responsibly—shows the character behind the brand.

October 2022: Biden Pardon Feature
Colin revealed his personal marijuana conviction history: “You face challenges with housing, loans, and banking, I mean with about everything… I would love to see people not get hurt for this anymore.”

For Rawlins County residents with conviction histories, this personal revelation shows Colin is not an outside entrepreneur—he’s someone who lived the consequences and built a legal business to prove the industry could operate with integrity.

April 2023: Texas Marijuana Laws
Colin’s “Renaissance” framing: “Right now is actually a pretty—like Renaissance—pretty important time that should be enjoyed now.”

This forward-looking perspective positions OilWell at the frontier of legal cannabis innovation.

The Through-Line: What the Media Record Reveals

Consistency across years. From 2019 to 2023, through every shift in Texas cannabis law, ABC13 returned to Colin as a primary source.

Breadth of expertise. The features span business, health, law, politics, and community advocacy—demonstrating comprehensive cannabis knowledge.

Community action. The COVID giveaway and proactive Delta-8 removal show values in action.

Personal stakes. Colin’s conviction history makes every quote more credible—he’s lived what he’s talking about.

Evolution of language. The media record tracks the growth of both the business and Colin’s public role.

For Rawlins County residents, this media validation from a major ABC affiliate establishes credibility that no amount of self-promotion could achieve. You can verify every segment. You can see the consistency. You can judge for yourself whether this is someone worth trusting with your health.

GENERAL KNOWLEDGE

Research Method and Evidence Weighting

This section prioritizes sources in the following order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters because the evidence base is not evenly distributed. Of the compounds in our formula, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, and in vitro pharmacology [1]-[29].

For Rawlins County residents who value scientific rigor—whether you’re a retired teacher, a healthcare worker, or just someone who wants proof before you try something—this evidence hierarchy matters. We don’t hide behind weak data. We tell you exactly what’s proven, what’s promising, and what’s still speculative.

Institutional Baseline from NIH and Related Sources

• The National Center for Complementary and Integrative Health (NCCIH) states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms [1].
• The FDA has not approved the cannabis plant itself for medical use, although purified CBD (Epidiolex) and synthetic THC-like drugs (dronabinol, nabilone) have specific approvals [1].
• Safety concerns highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination, and THC-vape lung-injury concerns [1].
• NCCIH warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

For Rawlins County residents, this institutional context is important. When your doctor expresses skepticism about cannabis products, they’re often referencing this exact literature. We acknowledge it. We don’t pretend the science says more than it does.

Cannabinoid Profiles

CBD

• Evidence profile: Strongest human evidence in our formula set, especially as purified product [1]-[6].
• Best supported: Purified CBD has the most credible human evidence in seizure disorders [1][2].
• Anxiety: A 2024 systematic review and meta-analysis covering 316 participants reported statistically significant anxiolytic signal, but authors stressed the clinical sample remains limited [3].
• Pain: A 2024 systematic review concluded the pain literature is promising but heterogeneous, with trial quality limiting confidence [4].
• Sleep: A 2023 insomnia review found literature remains methodologically weak [5].
• Safety: A 2023 systematic review found real signal for liver enzyme elevation, especially relevant for concentrated oral products and polypharmacy settings [6]. NCCIH flags diarrhea, sleepiness, appetite change, mood effects, liver-function abnormalities, and drug-drug interactions [1].

CBG

• Evidence profile: Mostly review-level and preclinical; human evidence remains sparse [7][8].
• Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from THC and CBD, interacting with cannabinoid receptors, alpha-2 adrenoceptors, and 5-HT1A-related signaling [7].
• Research areas: Reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses [7][8].
• Caution: A 2021 pharmacology review notes CBG is already being sold commercially while the evidence base remains thin, meaning claims frequently outrun the science [7].

Delta-8 THC

• Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC [9]-[11].
• Comparative pharmacology: A 2022 review concluded delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity, but appears less potent than delta-9 THC [9].
• Public health: A 2023 scoping review found the delta-8 evidence base is dominated by animal studies, product chemistry, and public-health concerns rather than strong human trials. Reports of adverse consequences emphasize regulatory and product-quality concerns [10].
• Manufacturing: A 2024 review notes commercial delta-8 interest is tied to greater stability and easier synthesis relative to naturally scarce plant levels, which is part of why product-byproduct and lab-testing questions matter [11].

THCa

• Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence [12].
• What it is: THCa is the acidic precursor of THC and may represent a large share of THC-related content in raw plant material. It decarboxylates into THC during heating and can change over time during storage and processing [12].
• Psychoactivity: THCa itself does not produce psychoactive effects associated with THC in humans, but this only holds if the molecule stays in its acidic form and is not substantially decarboxylated [12].
• Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes [12].

Delta-9 THC

• Evidence profile: Strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden [1][13]-[15].
• Institutionally best supported: NCCIH identifies THC-containing medicines as relevant to chemotherapy-related nausea and vomiting, appetite/weight loss in HIV/AIDS, and some multiple-sclerosis- and pain-related outcomes [1].
• Pain evidence: A 2022 systematic review found products with high THC content may provide short-term pain benefit but also increased dizziness, sedation, nausea, and treatment discontinuation [13].
• Pharmacokinetics: Inhaled THC produces effects within seconds to minutes, peaks in 15-30 minutes, and tapers over a few hours; oral THC has later onset, later peak, and longer duration [14].
• Mental health risk: A 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis or schizophrenia outcomes and cannabis use disorder, with concerning signals for anxiety and depression [15].
• Broader safety: Institutional literature describes anxiety/panic at high doses, tachycardia, blood pressure changes, dependency potential, withdrawal, pregnancy concerns, and vape-related lung injury [1][14][15].

CBN

• Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data [12][16][17].
• What it’s marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than the market suggests [16][17].
• Best review: A 2021 narrative review on CBN and sleep screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or polysomnography that could substantiate strong sleep-promoting claims [16].
• Broader sleep literature: A 2024 updated review concluded cannabinoid sleep research still doesn’t match the scale of real-world use, and the need for better-designed trials remains substantial [17].

CBC

• Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical or review-based [18][19].
• Pharmacology: A 2024 review argues CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior, highlighting antinociceptive, antibacterial, and anti-seizure areas as especially interesting [18].
• Older literature: Review literature reports anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, and possible neurobiological or antiproliferative relevance, but these are not strong evidence for patient-facing claims [19].
• Safety caveat: The 2024 CBC review explicitly notes over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety [18].

Terpene Profiles

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models. Robust proof of clinically meaningful entourage effects in humans remains limited [20][29].

Limonene

• Evidence: Largely review and preclinical, with useful safety literature [20]-[22].
• Potential activity: A 2021 review describes antioxidant, anti-inflammatory, cardioprotective, gastroprotective, and immune-modulatory possibilities, but most claims come from nonhuman or non-cannabis literature [21].
• Safety: Limonene oxidation products, especially hydroperoxides, are clinically relevant contact allergens [22].

Myrcene

• Evidence: Mostly preclinical, with very limited human evidence [20][23].
• Research: A 2021 review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties, but explicitly states human studies are lacking [23].
• Caution: Claims that myrcene reliably causes sedation remain interesting hypotheses rather than settled clinical facts [20][23].

Caryophyllene

• Evidence: Among the most mechanistically interesting because of direct CB2 receptor agonism, but still mostly preclinical [24].
• Why it stands out: A 2021 review describes beta-caryophyllene as a selective CB2 receptor agonist, unusual and especially relevant pharmacologically [24].
• Research themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, and gastroprotective actions are discussed, but human clinical confirmation remains limited [24].

Pinene

• Evidence: Promising preclinical literature, weak human confirmation [20][25].
• Brain health: A 2021 review found antioxidant, anti-inflammatory, and neuroprotective signals justifying future study, but emphasized well-designed clinical trials are lacking [25].

Linalool

• Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research: Discussed in relation to stress, mood, and brain-health pharmacology, but human trials remain limited [25][26].
• Safety: Oxidized linalool hydroperoxides are recognized allergens [22].

Humulene

• Evidence: Translationally interesting, but still early [20][27].
• Findings: A 2024 scoping review found broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties, but these findings are valuable for hypothesis generation, not consistent human efficacy [27].

Terpinolene

• Evidence: Least clinically characterized in this list [20][28].
• Research: A 2021 systematic review screened 2,449 records and concluded the evidence base is dominated by in silico, in vitro, and animal studies rather than human trials [28].

Research Limits and Interpretation

• The evidence base is highly uneven. CBD and delta-9 THC can support the most detailed human-facing statements; the rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting precisely because they are underexplored, but that also means claims around them often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, and dose variability all materially affect interpretation [1][10][11][14].
• For THCa, chemistry is destiny: storage and heating can change the actual exposure profile by converting acidic cannabinoids into neutral cannabinoids [12].

Common Overstatements to Avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: The specific sleep evidence for CBN remains weak, with no strong validated-trial base [16][17].

• Overstatement: Myrcene is a proven human sedative that explains couch-lock.
  More accurate: Myrcene has plausible preclinical bioactivity, but direct human proof is limited [20][23].

• Overstatement: Terpenes have proven entourage effects in patients.
  More accurate: Entourage hypotheses are influential, but robust clinical proof remains limited [20][29].

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself is not THC, but heating converts THCa into THC, changing exposure [12].

• Overstatement: Delta-8 THC is safe because it’s hemp-derived.
  More accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and has manufacturing-quality concerns [9]-[11].

Practical Takeaways for Rawlins County

• The most evidence-developed actives in our formulas are CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild—it’s a psychoactive cannabinoid with less robust safety characterization.
• THCa meaningfully changes with processing and should not be interpreted the same way in raw vs. heated formats.
• CBG, CBN, and CBC are scientifically credible but clinically immature compared to CBD and THC.
• The listed terpenes are likely relevant to aroma, flavor, and potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully.

References [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026.

2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238.

3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049.

4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438.

5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229.

6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752.

7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212.

8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471.

9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933.

10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028.

11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249.

12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130.

13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153.

14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360.

15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440.

16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371.

17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727.

18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213.

19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364.

20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543.

21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566.

22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12.

23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666.

24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639.

25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211.

26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092.

27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674.

28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768.

29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364.

RSO SUBLINGUAL OIL FORMULA

Cannabinoid	Amount
CBD	4,500mg
CBG	3,000mg
Delta-8 THC	6,000mg
THCa	1,500mg
Delta-9 THC	90mg
CBN	750mg
CBC	750mg
Total Cannabinoids	16,590mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30mL bottle
• Active cannabinoids per mL: 553mg
• Carrier: Organic MCT oil
• Onset: 15-45 minutes
• Duration: 4-6 hours
• Price: $129.99

For Rawlins County residents, this formula represents one of the most comprehensive multi-cannabinoid products legally available. The 553mg/mL concentration means each 0.1mL dropper increment delivers 55.3mg of total cannabinoids—precise dosing for careful titration.

How to use in Rawlins County:

• Raw (non-psychoactive): Place under tongue, hold 60 seconds, swallow. No impairment. Safe for daytime use, driving, operating equipment.
• Activated (psychoactive): Heat desired amount at 260°F for 45-60 minutes in oven-safe glass. Cool, then use sublingually. Provides full THC experience.
• With food: Taking with a fatty meal (beef, dairy, etc.) may enhance absorption due to MCT oil carrier.

RSO VAPE CARTRIDGE FORMULA

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 Gram cartridge
• Total cannabinoids: 900mg+
• Thread: 510-thread (universal battery compatible)
• Onset: 1-2 minutes
• Duration: 2-4 hours
• Price: $49.99

For Rawlins County residents needing rapid relief, the vape format delivers. The 1-2 minute onset is ideal for breakthrough pain, panic attacks, or sudden nausea. The 510-thread compatibility means it works with standard vape batteries available at convenience stores throughout Kansas.

Important: Vaping automatically decarboxylates THCa to delta-9 THC. Each puff delivers activated cannabinoids. This is the fastest delivery method but also the shortest duration—ideal for acute episodes, not sustained relief.

TERPENE PROFILE (BOTH PRODUCTS)

• Limonene: Citrus-bright aroma, potential mood elevation
• Myrcene: Earthy, musky base note, potential relaxation
• Caryophyllene: Pepper/spice scent, CB2 receptor agonist, anti-inflammatory potential
• Pinene: Forest-fresh pine aroma, potential alertness
• Linalool: Floral, lavender-like, potential calming effects
• Humulene: Earthy, woody, potential anti-inflammatory properties
• Terpinolene: Piney, fruity, sparkling top note

For Rawlins County residents familiar with essential oils or aromatherapy, this terpene profile provides a sensory experience that complements the cannabinoid effects. The aromas are natural, derived from live terpenes, not synthetic additives.

FINAL THOUGHTS FOR RAWLINS COUNTY

Rawlins County, Kansas, is a place where people take care of each other. Where a handshake still means something. Where you help your neighbor because it’s the right thing to do, not because there’s something in it for you. That’s the ethos we built OilWell Cannabis on.

We didn’t start this company in a boardroom. We started it because a dog named Bentley got up and walked when the vets said he wouldn’t. We started it because Colin faced a choice between pharmaceutical addiction and finding another way—and he found it in cannabinoids. We started it because we believe people deserve honest information, not hype.

For Rawlins County residents dealing with chronic pain from years of physical labor, with PTSD from military service, with the anxiety that comes from economic uncertainty, with cancer that conventional medicine is struggling to treat—we offer a legal, evidence-informed option.

Our product is Farm Bill compliant. It ships directly to your door in Atwood, McDonald, Herndon, or anywhere in Rawlins County. It’s lab-tested and transparent. And we publish our complete formula so that if you can’t afford it, you can make your own.

We’re not here to replace your doctor. We’re here to give you another tool for your toolbox—one that might help when other tools have failed.

Order today: Visit oilwellcbd.com or call (832) 416-2816. We ship to Rawlins County within 2-3 business days.

Age requirement: 21+ only.

FDA disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Consult your healthcare provider: Especially if you have a medical condition, take medications, are pregnant or nursing, or have health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Legal compliance: Buyer is responsible for verifying local laws. Product contains less than 0.3% delta-9 THC by dry weight. THCa converts to delta-9 THC when heated. International customers accept all customs and legal responsibility.

For Rawlins County, Kansas, this is your comprehensive guide to modern, legal, multi-cannabinoid RSO. We hope it serves you well.